Clinical trials: Fentanyl
Pain
Comparison of Two Dosage Strengths of Transdermal Fentanyl Versus Transdermal Buprenorphine and Placebo in Acute Pain Models in Healthy Volunteers.
The primary objective of this pilot trial is to identify pain model(s) which allow(s) to compare and differentiate the analgesic effects between transdermal fentanyl 25µg/h, transdermal fentanyl 12µg/h and placebo in a dose…
- Trial name
- NCT00886002
- Testing
- Fentanyl; Buprenorphine; Naloxone
- Volunteers
- 20 people
- Sponsor
- Janssen-Cilag A.G., Switzerland
Pain, Postoperative
An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery
The purpose of this study is to evaluate the mobilization characteristics, clinical use, safety and Ease of Care (EOC) of a fentanyl Iontophoretic Transdermal Patient Controlled Analgesia (PCA) system (Ionsys) and morphine…
- Trial name
- NCT00766506
- Testing
- Fentanyl IONSYS, Morphine IV PCA
- Where
- 7 sites in United Kingdom
- Volunteers
- 108 people
- Sponsor
- Janssen-Cilag Ltd.
Breakthrough Pain, Cancer
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks.
- Trial name
- GENISIS (NCT00994760)
- Testing
- Instanyl (Intranasal Fentanyl)
- Where
- 168 sites in Germany
- Volunteers
- 131 people
- Sponsor
- Takeda
Chronic Pain
A Study to Assess the Safety, Dose Conversion, and Dose Individualization of Duragesic® (Fentanyl Transdermal Patch) in the Treatment of Children With Chronic Pain Requiring Narcotic Pain Relief Therapy
The objective of this study is to assess the safety of treatment with Duragesic® (a transdermal patch delivering the narcotic pain-reliever fentanyl) in doses of 12.5, 25, 50, 75 and 100 micrograms/hour in pediatric subjects…
- Trial name
- NCT00271466
- Testing
- Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)
- Volunteers
- 199 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Pain
Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain
Evaluate the efficacy of treatment with the fentanyl buccal tablet (FBT) compared with immediate release oxycodone treatment in alleviating breakthrough pain (BTP) in opioid tolerant patients with chronic pain.
- Trial name
- NCT00813488
- Testing
- Fentanyl Buccal Tablet, Immediate release oxycodone
- Where
- 50 sites in United States
- Volunteers
- 213 people
- Sponsor
- Cephalon
Severe, Chronic Pain
Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain
The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).
- Trial name
- MATRIX II (NCT00556270)
- Testing
- Matrifen
- Where
- 815 sites in Germany
- Volunteers
- 3,000 people
- Sponsor
- Nycomed
Pain, Cancer
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.
- Trial name
- NCT00105937
- Testing
- OraVescent fentanyl citrate
- Where
- 43 sites in United States
- Volunteers
- 300 people
- Sponsor
- Cephalon
Pharmacokinetics and Pharmacodynamics
Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects
The primary objective of this study is to determine the pharmacokinetic and pharmacodynamic relationship of a single dose of fentanyl sublingual spray in opioid naive subjects.
- Trial name
- NCT02576353
- Testing
- Fentanyl, Fentanyl Citrate
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- INSYS Therapeutics Inc
Fentanyl Overdose, Fentanyl Poisoning
A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CS-1103 (1,000 mg), given by intravenous (IV) infusion in healthy participants in the presence of a clinically relevant dose of…
- Trial name
- NCT07459166
- Testing
- Naloxone Hydrochloride, Fentanyl, Sterile Saline
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Clear Scientific, Inc.
Chronic Pain
Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain
The purpose of this study is to confirm effectiveness and safety of fentanyl transdermal patch Durogesic® D-Trans for treatment of chronic pain in participants with chronic non-cancer pain.
- Trial name
- NCT01902524
- Testing
- Fentanyl-TTS
- Where
- South Korea
- Volunteers
- 65 people
- Sponsor
- Janssen Korea, Ltd., Korea
Opioid Overdose
Pharmacodynamic Evaluation of Intramuscular Nalmefene Autoinjector 1.5 mg Compared to Intranasal Narcan 4 mg
The purpose of this study is to determine the pharmacodynamics (change in minute ventilation) of nalmefene when given as an autoinjector intramuscularly (IM; into the thigh) compared to naloxone when given intranasally (IN; into…
- Trial name
- NCT06719986
- Testing
- Nalmefene HCl injection, Naloxone HCl intranasal
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Chronic Pain
A Study of JNS020QD in Patients With Chronic Pain
The purpose of this study is to evaluate the efficacy and safety of JNS020QD in patients with moderate to severe chronic pain who switched from opioid analgesics, as well as the safety and efficacy of long-term treatment (52…
- Trial name
- NCT01493245
- Testing
- JNS020QD
- Where
- 18 sites in Japan
- Volunteers
- 77 people
- Sponsor
- Janssen Pharmaceutical K.K.
Breakthrough Pain, Cancer
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
The purpose of the study is to assess the clinical effectiveness of Fentanyl ETHYPHARM when used to relieve breakthrough pain (BTP) in opioid-treated cancer patients.
- Trial name
- ETHYFYL (NCT01842893)
- Testing
- Fentanyl Ethypharm
- Where
- Czechia
- Volunteers
- 91 people
- Sponsor
- Ethypharm
Pain
A Study to Evaluate the Safety and Effectiveness of Fentanyl-TTS Compared to Weak Opioids in Patients With Moderate to Severe Chronic Cancer Pain Previously Treated With NSAIDS (Non-steroidal Anti-inflammatory Drugs).
To show, using the analgesic WHO scale, that fentanyl-TTS may be directly used for treating moderate to severe cancer pain in patients treated with NSAIDs, acetaminophen, or metamizole (first step drugs) avoiding the second step…
- Trial name
- NCT00576017
- Testing
- Fentanyl-TTS
- Volunteers
- 19 people
- Sponsor
- Janssen-Cilag, S.A.
Chronic Neuropathic Pain
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Neuropathic Pain
- Trial name
- NCT00214955
- Testing
- ORAVESCENT Fentanyl Citrate
- Where
- 17 sites in United States
- Volunteers
- 120 people
- Sponsor
- Cephalon
Cancers, Pain
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00458510
- Testing
- Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
- Volunteers
- 403 people
- Sponsor
- Archimedes Development Ltd
Pain, Postoperative
Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).
"This study is a single-center, randomized, open-label, 3-period, 5-treatment, 6-sequence design. A total of 54 eligible subjects will receive three total treatments; one with intravenous (IV) infusion and two with the Study…
- Trial name
- NCT01750060
- Testing
- Fentanyl, Naltrexone
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Incline Therapeutics, Inc.
Biological Availability
Pharmacokinetics of Fentanyl Following Intravenous and Oral Routes of Administration in Healthy Volunteers
The purpose of the study is to compare the pharmacokinetics of fentanyl following i.v. and oral administration in healthy volunteers, and to assess the bioavailability of fentanyl following oral administration.
- Trial name
- NCT00714558
- Testing
- Fentanyl citrate; Naltrexone; Naloxone
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Alza Corporation, DE, USA
Pain, Postoperative, Analgesia
A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump
The purpose of this study is to compare two pain medications delivered by two different forms of patient-controlled analgesia (PCA) management systems: the Fentanyl HCl Patient-Controlled Transdermal System (E-TRANS fentanyl) and…
- Trial name
- NCT00264485
- Testing
- E-TRANS Fentanyl hydrochloride; Morphine
- Volunteers
- 799 people
- Sponsor
- Alza Corporation, DE, USA
Cancer Pain
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00459277
- Testing
- Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Archimedes Development Ltd